Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 9/20 | 0.38 |
| ▸ | PPARA | Q07869 | 9/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25160199 | 0.85 | PPARD (0.48) | HSD17B3ROCK2PPARDPPARAPPARG | |
| SCHEMBL25160757 | 0.84 | PPARG (0.50) | HSD17B3ROCK2PPARDPPARAPPARG | |
| SCHEMBL22349797 | 0.83 | PPARD (0.48) | HSD17B3ROCK2PPARDPPARAPPARG | |
| SCHEMBL16196902 | 0.83 | PPARD (0.48) | HSD17B3ROCK2PPARDPPARAPPARG | |
| SCHEMBL20644446 | 0.83 | PPARD (0.51) | HSD17B3ROCK2PPARDPPARAPPARG | |
| SCHEMBL22349793 | 0.83 | PPARD (0.48) | HSD17B3ROCK2PPARDPPARAPPARG | |
| SCHEMBL22349850 | 0.83 | ALDH1A1 (0.47) | ROCK2PPARDPPARAPPARGSMN1; SMN2 | |
| SCHEMBL9665897 | 0.76 | MAPT (0.65) | HSD17B3MAPTKDM4EGAASMN1; SMN2 | |
| SCHEMBL20639871 | 0.76 | MAPT (0.49) | HSD17B3PPARDPPARAPPARGMAPT | |
| SCHEMBL22349788 | 0.74 | ELANE (0.48) | ROCK2MAPTGAAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321082-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321082-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321082-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | RABL3, VAPA, VAPB | HSD17B3 3037/4885ROCK2 2976/4885PPARD 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.